Product Details
| Product Name:
NITD008 |
CAS No.:
1044589-82-3 |
| Purity:
98.04% |
Supply Ability:
10g |
| Release date:
2026/09/10 |
Product Introduction
Bioactivity
| Name | NITD008 |
| Description | NITD008 (7-Deaza-2'-C-acetylene-adenosine) is a potent and selective adenosine nucleoside inhibitor.NITD008 is an adenosine nucleoside analog with broad-spectrum antiviral activity that inhibits dengue, animal cupripoxvirus, and Zika virus. |
| In vitro | NITD008 exhibits potent inhibition against various viruses, including Dengue virus (DENV), West Nile virus, yellow fever virus, and Poissan virus. In the case of DENV-2, NITD008 inhibits the virus in a dose-responsive manner, with an EC50 value of 0.64 μM. Treatment with 9 μM of the compound Result in a reduction in viral titer by >104-fold[1].Furthermore, NITD008 also demonstrates inhibitory activity against a luciferase-reporting replicon of hepatitis C virus (HCV, genotype 1b), a member of the genus Hepacivirus, with an EC50 value of 0.11 μM[1]. |
| In vivo | NITD008, with good pharmacokinetic properties, is orally bioavailable. The formulation using 6 N HCl (1.5 equimolar amount), 1 N NaOH (pH adjusted to 3.5), and 100 mM citrate buffer (pH 3.5) yields the best pharmacokinetic parameters. Following intravenous (i.v.) injection, NITD008 demonstrates a high volume of distribution (3.71 L/kg) and low systemic clearance (31.11 mL/min per kg), resulting in a long elimination half-life (t1/2=4.99 h).
After oral dosing, NITD008 is rapidly absorbed (time of peak plasma concentration=0.5 h), reaching a maximal plasma concentration of 3 μM, with a bioavailability of 48%. When administered immediately after viral infection, a dose of 1 mg/kg of NITD008 does not reduce mortality, but treatment with 3 mg/kg provides partial protection, and doses of ≥10 mg/kg completely protect infected mice from death. NITD008 effectively suppresses peak viremia, reduces cytokine elevation, and prevents mortality in the infected mice[1]. |
| Storage | Store at low temperature
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 50 mg/mL (172.25 mM), Sonication is recommended.
10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (6.89 mM), Sonication is recommended.
|
| Keywords | NITD-008 | NITD008 | NITD 008 | DENV-2 | Dengue Fever virus | Antiviral | Adenosine kinase |
| Inhibitors Related | 5-Fluorouracil | Adenine hemisulfate | Erythromycin thiocyanate | Guanidine hydrochloride | Hexane-1,6-diol | 1,4-Naphthoquinone | Penicillin G potassium | Adenine | (E)-3-(p-Tolyl)acrylaldehyde | Carbazole | Thymidine | Usnic Acid |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
Recommended supplier
| Product name |
Price |
|
Suppliers |
Update time |
|
|
|
|
Anhui Ruihan Technology Co., Ltd
|
2023-08-21 |
United States